Drug Interactions Associated with Cytochrome P-450 Enzymes

REFERENCES

• Hansten P D. Drug Interactions. Applied Therapeutics: The clinical use of drugs, 6th edition, L Y Young, M A Koda-Kimble. Applied Therapeutics, Inc. 1995; 3–1
   Google Scholar
• Pollack B G. Recent developments in drug metabolism of relevance to psychiatrists. Harv Rev Psychiatry. 1994; 2: 204
   PubMed Web of Science ®Google Scholar
• Slaughter R L, Edwards D J. Recent Advances: The cytochrome P450 enzymes. Ann Pharmacother. 1995; 29: 619–624
   PubMed Web of Science ®Google Scholar
• Krishna D, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet. 1994; 26: 144
   PubMed Web of Science ®Google Scholar
• Nebert D W, Adesnick M, et al. The P450 gene superfamily: Recommended nomenclature. DNA. 1987; 6: 1
   PubMedGoogle Scholar
• Nebert D W, Nelson D R, et al. The P-450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA Seq. 1989; 8: 1
   Google Scholar
• Nebert D W, Nelson D R, et al. The P-450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 1991; 10: 1
   PubMed Web of Science ®Google Scholar
• Nelson D R, Kamataki T, et al. The P-450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993; 12: 1
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994; 270: 414
   PubMed Web of Science ®Google Scholar
• Quinn D L, Day R O. Drug interactions of clinical importance: An updated guide. Drug Safety. 1995; 12: 393
   PubMed Web of Science ®Google Scholar
• Young D, Midha K K, et al. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P45011D6. Eur J Clin Pharmacol. 1993; 44: 433
   PubMed Web of Science ®Google Scholar
• Relling M V, Lin J S, et al. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther. 1992; 52: 643
   PubMed Web of Science ®Google Scholar
• Butler M A, Lang N P, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992; 2: 116
   PubMedGoogle Scholar
• Fuhr U, Rost K L. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics. 1994; 4: 109
   PubMedGoogle Scholar
• Wrighton S A, Stevens J C. The human hepatic cytochromes P-450 involved in drug metabolism. Crit Rev Toxicol. 1992; 22: 1
   PubMed Web of Science ®Google Scholar
• Kalow W, Tang B K. Caffeine as a metabolic probe: exploration of the enzyme-inducing effects of cigarette smoking. Clin Pharmacol Ther. 1991; 49: 44
   PubMed Web of Science ®Google Scholar
• Wilkinson G R, Guengerich F P, et al. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther. 1989; 43: 53
   PubMed Web of Science ®Google Scholar
• Nix D E, et al. Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green. J Antimicrobial Chemother 1987; 19: 263
   PubMed Web of Science ®Google Scholar
• Product information. Cognex (tacrine). Parke-Davis, Morris Plains, NJ 1993
   Google Scholar
• Pollock B G, Perel J M, et al. S-mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol. 1991; 40: 609
   PubMed Web of Science ®Google Scholar
• Wedlund P J, Aslanian W S, et al. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984; 36: 773
   PubMed Web of Science ®Google Scholar
• Nakamura K, Goto F, et al. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoinhydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985; 38: 402
   PubMed Web of Science ®Google Scholar
• Connelly J F. Vigabatrin. Ann Pharmacother. 1993; 27: 197
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Hentom T K, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Then 1989; 45: 348
   PubMed Web of Science ®Google Scholar
• Guengerich F P, Muller-Enoch D, et al. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30: 287
   PubMed Web of Science ®Google Scholar
• Kay L, et al. Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol. 1985; 20: 323
   PubMed Web of Science ®Google Scholar
• Klotz U, et al. Delayed clearance of diazepam due to cimetidine. N Engl J Med. 1980; 302: 1012
   PubMed Web of Science ®Google Scholar
• Tatro D S. Fluvoxamine drug interactions. Drug Newsletter. 1995; 14: 20
   Google Scholar
• Derenne F, Joanne C, et al. Debrisoquine oxidative phenotyping and psychiatric drug treatment. Eur J Clin Pharmacol. 1989; 36: 53
   PubMed Web of Science ®Google Scholar
• Brosen K., Gram L F. Sparteine oxidation polymorphism in Denmark. Acta Pharmacologica et Toxicologica. 1985; 57: 357
   PubMedGoogle Scholar
• Rettie A E, Korzekwa K R, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992; 5: 54
   PubMed Web of Science ®Google Scholar
• Skjelbo E, Brosen K, et al. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther. 1991; 49: 18
   PubMed Web of Science ®Google Scholar
• Alvan G, Balant L P, et al. European consensus conference on pharmacogenetics. Commission of the European Communities, Brussels 1990
   Google Scholar
• Sindrup H S, Arendt-Nelson L, et al. The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol. 1992; 42: 587
   PubMed Web of Science ®Google Scholar
• Tateishi T, et al. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol, and atenolol. Eur J Clin Pharmacol. 1989; 36: 67
   PubMed Web of Science ®Google Scholar
• Kharasch. Biotransformation of sevoflurane. Anesth Analg 1995; 81: S27–38
   PubMed Web of Science ®Google Scholar
• Kharasch E D, Thummel K E. Identification of cytochrome P-450 2E1 as the predominant enzyme catalyzing human liver microsomal defuorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993; 79: 795–807
   PubMed Web of Science ®Google Scholar
• Wesley R L, Chen Y, et al. Mechanism of the cardiotoxic actions of terfenadine. JAM. 1993; 269: 1532
   PubMed Web of Science ®Google Scholar
• Aamj Hollander. Effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther. 1995; 57: 318
   PubMed Web of Science ®Google Scholar
• information Product. Propulsid (cisapride). Janssen Pharmaceutica, Titusville, NJ 1995
   Google Scholar
• Eller M G, et al. Pharmacokinetic interaction between terfenadine and ketoconazole. Clin Pharmacol Ther. 1991; 49: 130
   Web of Science ®Google Scholar
• Tacke U, Leinonen E, et al. Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations. J Clin Psychopharmacol. 1992; 12: 262
   PubMed Web of Science ®Google Scholar
• Bluhm R E, Wilkinson G R, et al. Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. Clin Pharmacol Ther. 1993; 53: 89
   PubMed Web of Science ®Google Scholar
• Spina E, Ancione M, et al. Polymorphic debrisoquine oxidation and acute neuroleptic-induced side effects. Eur J Clin Pharmacol. 1992; 42: 347
   PubMed Web of Science ®Google Scholar
• Finley P R. Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother. 1994; 28: 1359
   PubMed Web of Science ®Google Scholar
• Popli A P, Baldessarini R J, et al. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry. 1994; 51: 666
   PubMed Web of Science ®Google Scholar
• Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmac. 1992; 34: 256
   PubMed Web of Science ®Google Scholar
• Otton S V, Wu D, et al. Inhibition by fluoxetine of cyctochrome P-450 2D6 activity. Clin Pharmacol Ther. 1993; 53: 401
   PubMed Web of Science ®Google Scholar
• Crewe H K, Lennard M S, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P-450 2D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992; 34: 262
   PubMed Web of Science ®Google Scholar
• De Vane C L. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994; 55: 38
   Web of Science ®Google Scholar
• Vandel S, Bertschy G, et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology. 1992; 25: 202
   PubMed Web of Science ®Google Scholar
• Llema A, Herraiz A G, et al. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther. 1993; 54: 606
   PubMed Web of Science ®Google Scholar
• Lennard M. Genetically determined adverse drug reactions involving metabolism. Drug Safety. 1993; 9(1)60
   PubMed Web of Science ®Google Scholar
• Buchert E, Wesley R L. Clinical implications of variable antiarrhythmic drug metabolism. Pharmacogenetics. 1992; 2: 2
   PubMedGoogle Scholar
• Soddoway L A, Thompson K, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation. 1987; 75: 785
   PubMed Web of Science ®Google Scholar
• Lee J T, Kroemer H K, et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med. 1990; 322: 1764
   PubMed Web of Science ®Google Scholar
• Sindrup H S, Arendt-Nelson L, et al. The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol. 1992; 42: 587
   PubMed Web of Science ®Google Scholar
• Desmeules J, Gascon M P, et al. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol. 1991; 41: 23
   PubMed Web of Science ®Google Scholar
• Sindrup H S, Brosen K, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther. 1990; 48: 686
   PubMed Web of Science ®Google Scholar
• Product information. Ultram (Tramadol). Ortho McNeil, March, Raritan, NJ 1995
   Google Scholar
• Grange J M, Winstanley P A, et al. Clinically significant drug interactions with antituberculosis agents. Drug Safety. 1994; 11: 242
   PubMed Web of Science ®Google Scholar
• von Rosensteil N A, Adam D. Macrolide antibiotics: Drug interactions of clinical significance. Drug Safety. 1995; 13: 105
   PubMed Web of Science ®Google Scholar
• Product information. Norvir (ritonavir). Abbott Laboratories, February, Chicago, IL 1996
   Google Scholar
• Product information. Invirase (saquinavir mesylate). Roche Laboratories, November, Nutley, NJ 1995
   Google Scholar
• Product information. Crixivan (indinavir sulfate). Merck and Co., Inc, March, West Point, PA 1996
   Google Scholar
• Trapnell C B, Narang P K, Li R, et al. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med. 1996; 124: 573–6
   PubMed Web of Science ®Google Scholar
• Armstrong M, Daly A K, et al. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet. 1992; 339: 1017
   PubMed Web of Science ®Google Scholar
• Smith C A, Gough A C, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet. 1992; 339: 1375
   PubMed Web of Science ®Google Scholar
• Eagger S, Levy R. Serum levels of tacrine in relation to clinical response in Alzheimer's disease. Int J Geriatr Psychology. 1992; 7: 115
   Web of Science ®Google Scholar
• Hansten P D, Horn J R. Drug Interactions and Updates. Applied Therapeutics, Inc. 1993; 331
   Google Scholar
• Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet. 1993; 25: 433
   PubMed Web of Science ®Google Scholar
• Graves N M. Felbamate. Ann Pharmacother. 1993; 27: 1073
   PubMed Web of Science ®Google Scholar
• Goa K L, Sorkin E M. Gabapentin: A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993; 46: 409
   PubMed Web of Science ®Google Scholar